Essa Pharma Inc Quick Ratio (EPIX) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Essa Pharma inc   (NASDAQ: EPIX)

Essa Pharma Inc 's Quick Ratio

EPIX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 41.85 above Essa Pharma Inc average.

Within Major Pharmaceutical Preparations industry 8 other companies have achieved higher Quick Ratio than Essa Pharma Inc in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 38 to 103.

Explain Quick Ratio?
How much Cash & cash equivalents EPIX´s has?
What are EPIX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EPIX Quick Ratio (Jun 30 2025)
Q3		 (Mar 31 2025)
Q2		 (Dec 31 2024)
Q1		 (Sep 30 2024)
Q4		 (Jun 30 2024)
Q3
Y / Y Current Liabilities Change -53.78 % -66.09 % 27.15 % -18.49 % 9.31 %
Y / Y Cash & cash equivalent Change -0.04 % -5.87 % 163.82 % 207.37 % 123.33 %
Quick Ratio MRQ 41.85 46.53 19.23 29.87 19.35
EPIX's Total Ranking # 103 # 38 # 68 # 55 # 37
Seq. Current Liabilities Change 10.73 % -61.76 % 39.71 % -21.86 % -18.76 %
Seq. Cash & cash equivalent Change -0.4 % -7.49 % -10.03 % 20.59 % -6.21 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 9
Healthcare Sector # 16
Overall Market # 103


Quick Ratio Statistics
High Average Low
49.51 19.55 1.08
(Sep 30 2020)   (Sep 30 2017)




Financial Statements
Essa Pharma Inc 's Current Liabilities $ 2 Millions Visit EPIX's Balance sheet
Essa Pharma Inc 's Cash & cash equivalent $ 86 Millions Visit EPIX's Balance sheet
Source of EPIX's Sales Visit EPIX's Sales by Geography


Cumulative Essa Pharma Inc 's Quick Ratio

EPIX's Quick Ratio for the trailling 12 Months

EPIX Quick Ratio

 (Jun 30 2025)
12 Months		 (Mar 31 2025)
12 Months		 (Dec 31 2024)
12 Months		 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months
Y / Y Current Liabilities TTM Growth -32 % -16.97 % 24.52 % 18.6 % 34.63 %
Y / Y Cash & cash equivalent TTM Growth 49.63 % 85.3 % 146.52 % 88.69 % 29.04 %
Quick Ratio TTM 30.19 25.26 20.55 18.42 13.72
Total Ranking TTM # 2536 # 1752 # 2241 # 2002 # 1580
Seq. Current Liabilities TTM Growth -16.34 % -19.82 % 6.02 % -4.38 % 2.15 %
Seq. Cash & cash equivalent TTM Growth -0.01 % -1.44 % 18.29 % 28.35 % 23.83 %

Quick ratio ranking by company, industry and sector >> Back to EPIX Financial Strength Comparisons >> Go to Compare EPIX Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Essa Pharma Inc 's average Cash & cash equivalent, this led to increase in in Essa Pharma Inc 's Quick Ratio to 30.19, Quick Ratio remained below EPIX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 444 other companies have achieved higher Quick Ratio than Essa Pharma Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from 1752 to 2536.

Explain Quick Ratio?
How much Cash & cash equivalents EPIX´s has?
What are EPIX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 445
Healthcare Sector # 838
Within the Market # 2536


trailing twelve months Quick Ratio Statistics
High Average Low
59.24 34.96 2.35
(Jun 30 2023)   (Sep 30 2018)




Companies with similar Quick Ratio in the quarter ending Jun 30 2025, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2025 MRQ Cash & cash equivalentJun 30 2025 MRQ Current Liabilities
Bridgebio Oncology Therapeutics Inc   79.56 $ 200.664  Millions$ 2.522  Millions
Gh Research Plc  73.65 $ 253.873  Millions$ 3.447  Millions
Benitec Biopharma Inc   67.54 $ 97.799  Millions$ 1.448  Millions
Structure Therapeutics Inc   53.95 $ 786.500  Millions$ 14.579  Millions
Disc Medicine Inc   51.95 $ 649.973  Millions$ 12.511  Millions
Janux Therapeutics Inc   46.59 $ 996.011  Millions$ 21.379  Millions
Essa Pharma inc   41.85 $ 85.975  Millions$ 2.054  Millions
Xbiotech Inc   39.65 $ 152.938  Millions$ 3.857  Millions
Roivant Sciences Ltd   39.55 $ 4,503.151  Millions$ 113.866  Millions
Apimeds Pharmaceuticals US, Inc.  36.67 $ 8.735  Millions$ 0.238  Millions
Belite Bio Inc  36.61 $ 352.932  Millions$ 9.641  Millions
Upstream Bio Inc   36.01 $ 393.581  Millions$ 10.929  Millions
Bright Minds Biosciences Inc   35.59 $ 63.669  Millions$ 1.789  Millions
Protagonist Therapeutics inc   30.59 $ 570.465  Millions$ 18.646  Millions
Edgewise Therapeutics inc   28.43 $ 593.992  Millions$ 20.896  Millions
Arca Biopharma Inc  27.12 $ 328.406  Millions$ 12.110  Millions
Inhibitor Therapeutics Inc   26.70 $ 3.738  Millions$ 0.140  Millions
Hoth Therapeutics Inc   26.26 $ 9.014  Millions$ 0.343  Millions
Viking Therapeutics Inc   25.63 $ 807.724  Millions$ 31.512  Millions
Bicara Therapeutics Inc   25.34 $ 436.606  Millions$ 17.227  Millions
Monopar Therapeutics Inc   24.94 $ 39.502  Millions$ 1.584  Millions
Design Therapeutics Inc   24.73 $ 216.276  Millions$ 8.747  Millions
Terns Pharmaceuticals Inc   24.43 $ 315.445  Millions$ 12.914  Millions
Contineum Therapeutics Inc   24.33 $ 175.484  Millions$ 7.214  Millions
Anebulo Pharmaceuticals Inc   23.84 $ 11.628  Millions$ 0.488  Millions
Fulcrum Therapeutics Inc   23.83 $ 214.111  Millions$ 8.985  Millions
Trevi Therapeutics Inc   22.77 $ 203.885  Millions$ 8.955  Millions
Rapport Therapeutics Inc   21.92 $ 260.447  Millions$ 11.879  Millions
Keros Therapeutics Inc   21.88 $ 690.215  Millions$ 31.552  Millions
Newamsterdam Pharma Company N v   21.63 $ 739.162  Millions$ 34.175  Millions

Date modified: 2026-09-08T17:33:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.